Viewing nowJanus Tablet 100 mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
White Life Science Co., Ltd.

MFDS item code 202100007 · Approved 2021.01.04 · Insurance code 625202150
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used alongside diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be administered as monotherapy initially, and in cases where blood sugar control is difficult with monotherapy due to previous non-use of diabetes medications, it is combined with metformin. It may also be used in conjunction if blood sugar is inadequately controlled with monotherapy of sulfonylurea, metformin, thiazolidinedione, or insulin. Furthermore, if blood sugar control remains insufficient after several combination therapies, this medication can be additionally used. This medication is employed at various stages of treatment to improve blood sugar control.
This medicine is administered at a dose of 100 mg once daily, either as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2) should receive 50 mg once daily. 4. Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2) should receive 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe hypersensitivity reactions after administration; therefore, if any allergic symptoms or skin abnormalities occur, use should be discontinued immediately, and a physician should be consulted. Additionally, this medication may induce severe pancreatic conditions such as pancreatitis, so if symptoms like abdominal pain, vomiting, or appetite loss arise, it should be discontinued immediately and medical personnel should be notified. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should not be administered in cases of allergy to this medication or its components. Patients with impaired renal function should have their dosage adjusted; regular renal function tests should be obtained, and administration should be conducted under medical supervision. This medication can increase the risk of hypoglycemia when used with other glucose-lowering medications, especially insulin or sulfonylureas, so attention should be paid to symptoms of hypoglycemia, with dosage adjustments made as needed. Side effects such as headache, upper respiratory infections, nasopharyngitis, diarrhea, etc., may occur during treatment; if these symptoms are severe or persistent, consult a physician. In cases of severe arthralgia or skin blistering, medication should be stopped immediately, and specialized medical attention should be sought. Pregnant or breastfeeding women are advised not to use this medication, and safety in children and adolescents under 18 years has not been established. Elderly patients may have a risk of reduced renal function, necessitating dosage adjustments and regular renal function tests. In cases of overdose, general treatment along with ECG monitoring is necessary as some may be removed by hemodialysis, so this should be considered if needed. This medication has a relatively low interaction with other drugs; however, caution is necessary when taking specific medications, hence all medications should be disclosed to medical personnel. Finally, while this medication does not majorly affect cardiovascular safety, immediate consultation with medical personnel is necessary if any abnormal symptoms occur during use.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is recommended to maintain the storage temperature between 1 to 30 degrees Celsius.
Beige round biconvex film-coated tablets
30 tablets/bottle, 90 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
White Life Science Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.